An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis | MicrobiomeTrials← Back to trialsNCT07459660
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-03-25Est. Completion: 2029-03
Enrollment target: 210 participants Locations- Clinical Site, Anaheim, California, United States
- Clinical Site, Doral, Florida, United States
- Clinical Site, Miami, Florida, United States
- Clinical Site, Miami, Florida, United States
- Clinical Site, Miami Gardens, Florida, United States
- Clinical Site, Orlando, Florida, United States
- Clinical Site, Pernik, Pernik, Bulgaria
- Clinical Site, Toulouse, France
Other microbiome trials you might be interested in
Psychosis Associated With Alzheimer's Disease
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of M…
Phoenix, United StatesEst. completion Dec 2027
Psychosis Associated With Alzheimer's Disease
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the …
Anaheim, United StatesEst. completion Sep 30, 2028